Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Unilife Corp | d627082d8k.htm |
| EX-99.2 - EX-99.2 - Unilife Corp | d627082dex992.htm |
Exhibit 99.1
Unilife Corporation Announces Financial Results
For Fiscal Year 2014 First Quarter
York, PA (November 11, 2013) Unilife Corporation (“Unilife” or “Company”) (NASDAQ:UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended September 30, 2013, (the first quarter of Fiscal Year 2014).
Recent Highlights
| • | In September 2013, Unilife announced the signing of a long-term supply contract with Sanofi. Unilife has agreed to supply Sanofi with the Unifill Finesse™, a customized device from its Unifill® platform of prefilled syringes with automatic, needle retraction, for use with the anti-thrombotic therapy Lovenox®/Clexane®. The contract period can extend up to 2024. In October 2013, Unilife received the first $5 million payment from Sanofi under the commercial supply agreement. Revenue from this payment has not yet been recognized, and was recorded as deferred revenue in the September 30, 2013 balance sheet. |
| • | Earlier today, Unilife announced another cornerstone agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to customize and supply devices from its platform of wearable injectors. Under this agreement, Unilife will supply MedImmune with customized devices from its platform of ReadyToGo™ wearable injectors. Several drug candidates from MedImmune’s portfolio may be selected for use with Unilife’s wearable injectors under the agreement. Unilife begins generating revenue starting in Q1 FY14 on the basis of customization and supply of its products to MedImmune. |
| • | Unilife continues to accelerate the expansion of its customer base, and has multiple customers in its commercial pipeline. Information regarding each customer partnership will be announced when it can be disclosed. |
Mr. Alan Shortall, CEO of Unilife, commented: “As I have said all along, fiscal year 2014 is the inflection point for Unilife when we begin to show rapidly increasing revenue. As such, we reported revenue of $3.2 million in the first quarter of Fiscal Year 2014, which is an increase of 360% over the same quarter in the prior year. Although the comparison is against a small base, it is significant in that it shows the inflection point in our revenue. From here, I expect the slope to be significant.
“As we continue to increase our investment in R&D and operations, which is increasingly offset by our revenue, we are also narrowing our operating loss. As such, we have reported a 10% decrease in operating loss for the first quarter compared with the prior year period. The loss per share has narrowed by 25% to $0.12, compared with the prior year period. I anticipate sequential quarterly growth in Fiscal Year 2014, as well as significant annual growth this fiscal year and beyond.
“We are focused on rapid and significant growth in the long-term. To accomplish this, we will continue to increase our investment in R&D and operations, much of which will be offset by our increasing revenue. I am pleased with the results we are getting from our investment in these areas. A look at the breadth and
quality of our product portfolio on our website shows how far we have come over the last two or three years. Although we can be cash flow positive this year, if we wanted to do so, it is not in the best long term interest of our shareholders. This is because limiting our investment in R&D today can dampen the growth we anticipate in 2017 and beyond,” Mr. Shortall concluded.
Financial Results for Three Months Ended September 30, 2013
Revenue for the three months ended September 30, 2013, was $3.2 million compared to $0.7 million for the same period in 2012.
The Company’s net loss for the three months ended September 30, 2013, was $11.2 million, or $0.12 per share, compared to a net loss of $12.5 million, or $0.16 per share, for the same period in 2012. Adjusted net loss for the three months ended September 30, 2013, was $7.1 million, or $0.08 per share, compared to $9.1 million, or $0.12 per share, for the same period in 2012. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense.
Unilife reported $9.4 million of total cash and cash equivalents, including $2.0 million in restricted cash as of September 30, 2013. This does not reflect the first $5 million payment from Sanofi under the commercial supply agreement, which was received in October 2013.
Conference Call Information
Management has scheduled a conference call for 4:30 p.m. U.S. EST on Monday, November 11, 2013, (Tuesday, November 12, 2013 at 6:30 a.m. AEDT), to review the Company’s financial results, customer partnerships and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a “live” listen-only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm.
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife’s global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.
Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
Non-GAAP Financial Measures
U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.
Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor’s understanding, of the Company’s core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.
| General: UNIS-G |
||||
| Investor Contacts (US): |
Analyst Enquiries | Investor Contacts (Australia) | ||
| Todd Fromer / Garth Russell |
Lynn Pieper | Jeff Carter | ||
| KCSA Strategic Communications |
Westwicke Partners | Unilife Corporation | ||
| P: + 1 212-682-6300 |
P: + 1 415-202-5678 | P: + 61 2 8346 6500 | ||
UNILIFE CORPORATION AND SUBSIDIARIES
Consolidated Balance Sheets
(unaudited)
| September 30, 2013 | June 30, 2013 | |||||||
| (in thousands, except share data) | ||||||||
| Assets |
||||||||
| Current Assets: |
||||||||
| Cash and cash equivalents |
$ | 7,416 | $ | 5,736 | ||||
| Restricted cash |
1,966 | 2,400 | ||||||
| Accounts receivable |
5,059 | 654 | ||||||
| Inventories |
72 | 71 | ||||||
| Prepaid expenses and other current assets |
284 | 409 | ||||||
|
|
|
|
|
|||||
| Total current assets |
14,797 | 9,270 | ||||||
| Property, plant and equipment, net |
45,724 | 46,106 | ||||||
| Goodwill |
11,712 | 11,498 | ||||||
| Intangible assets, net |
23 | 23 | ||||||
| Other assets |
1,162 | 1,504 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 73,418 | $ | 68,401 | ||||
|
|
|
|
|
|||||
| Liabilities and Stockholders’ Equity |
||||||||
| Current Liabilities: |
||||||||
| Accounts payable |
$ | 1,909 | $ | 3,428 | ||||
| Accrued expenses |
3,720 | 2,444 | ||||||
| Current portion of long-term debt |
2,719 | 3,826 | ||||||
| Deferred revenue |
115 | 3,010 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
8,463 | 12,708 | ||||||
| Long-term debt, less current portion |
19,752 | 20,045 | ||||||
| Deferred revenue |
5,050 | 50 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
33,265 | 32,803 | ||||||
|
|
|
|
|
|||||
| Stockholders’ Equity: |
||||||||
| Preferred stock, $0.01 par value, 50,000,000 shares authorized as of September 30, 2013; none issued or outstanding as of September 30, 2013 and June 30, 2013 |
— | — | ||||||
| Common stock, $0.01 par value, 250,000,000 shares authorized as of September 30, 2013; 100,520,211 and 95,602,558 shares issued, and 100,491,541 and 95,573,888 shares outstanding as of September 30, 2013 and June 30, 2013, respectively |
1,005 | 956 | ||||||
| Additional paid-in-capital |
283,646 | 268,157 | ||||||
| Accumulated deficit |
(247,076 | ) | (235,832 | ) | ||||
| Accumulated other comprehensive income |
2,718 | 2,457 | ||||||
| Treasury stock, at cost, 28,670 shares as of September 30, 2013 and June 30, 2013, respectively |
(140 | ) | (140 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
40,153 | 35,598 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 73,418 | $ | 68,401 | ||||
|
|
|
|
|
|||||
UNILIFE CORPORATION AND SUBSIDIARIES
Consolidated Statements of Operations
(unaudited)
| Three Months Ended September 30, |
||||||||
| 2013 | 2012 | |||||||
| (in thousands, except per share data) | ||||||||
| Revenue |
$ | 3,187 | $ | 692 | ||||
| Cost of product sales |
— | 59 | ||||||
|
|
|
|
|
|||||
| Gross profit |
3,187 | 633 | ||||||
|
|
|
|
|
|||||
| Operating expenses: |
||||||||
| Research and development |
6,399 | 4,738 | ||||||
| Selling, general and administrative |
6,520 | 6,577 | ||||||
| Depreciation and amortization |
1,042 | 1,223 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
13,961 | 12,538 | ||||||
|
|
|
|
|
|||||
| Operating loss |
(10,774 | ) | (11,905 | ) | ||||
| Interest expense |
480 | 616 | ||||||
| Interest income |
(6 | ) | (24 | ) | ||||
| Other expense, net |
(4 | ) | — | |||||
|
|
|
|
|
|||||
| Net loss |
(11,244 | ) | (12,497 | ) | ||||
|
|
|
|
|
|||||
| Net loss per share: |
||||||||
| Basic and diluted net loss per share |
$ | (0.12 | ) | $ | (0.16 | ) | ||
|
|
|
|
|
|||||
UNILIFE CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Measure
(unaudited)
| Three Months Ended September 30, |
||||||||
| 2013 | 2012 | |||||||
| (in thousands, except per share data) | ||||||||
| Net loss |
$ | (11,244 | ) | $ | (12,497 | ) | ||
| Share-based compensation expense |
2,636 | 1,555 | ||||||
| Depreciation and amortization |
1,042 | 1,223 | ||||||
| Interest expense |
480 | 616 | ||||||
|
|
|
|
|
|||||
| Adjusted net loss |
$ | (7,086 | ) | $ | (9,103 | ) | ||
|
|
|
|
|
|||||
| Adjusted net loss per share – diluted |
$ | (0.08 | ) | $ | (0.12 | ) | ||
|
|
|
|
|
|||||